BioTuesdays

Author - Sydney Stewart

Adamas Pharmaceuticals Logo
Markets

SVB Leerink halves Adamas Pharma PT to $6

SVB Leerink lowered its price target for Adamas Pharmaceuticals (NASDAQ:ADMS) to $6 from $13, saying the mixed Phase 3 INROADS data are not good enough. In afternoon trading on Dec. 17, the stock was quoted at $4.15...

December 17, 2019
Axsome Therapeutics
Markets

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...

December 4, 2019
TELA Bio
Markets

Piper Jaffray starts TELA Bio at OW; PT $17

Piper Jaffray initiated coverage of TELA Bio (NASDAQ:TELA) with an “overweight” rating and $17 price target. The stock closed at $12.31 on Dec. 2. TELA is a regenerative medicine company, with products used in hernia...

December 3, 2019
Galera Therapeutics
Markets

BTIG starts Galera Therapeutics at buy; PT $30

BTIG launched coverage of Galera Therapeutics (NASDAQ:GRTX) with a “buy” rating and $30 price target. The stock closed at $12.53. Galera is focused on developing superoxide dismutase mimetics, first‐in‐class medicines...

December 2, 2019
Zenabis Logo
Developments

Zenabis completes over-subscribed rights offering

Zenabis Global’s (TSX:ZENA) rights offering was over-subscribed, resulting in the issuance of a maximum of 139,086,624 common shares at a price of 15 cents each for gross proceeds of about $20.8-million. The company is...

November 29, 2019
Adamis Pharma
Markets

Maxim cuts Adamis Pharma to hold; withdraws PT

Maxim Group downgraded Adamis Pharmaceuticals (NASDAQ:ADMP) to “hold” from “buy” and withdrew its previous $3 price target after the company received a complete response letter (CRL) from the FDA regarding the NDA for...

November 25, 2019
Hepion Pharmaceuticals
Markets

Brookline starts Hepion Pharma at buy; PT $12

Brookline Capital Markets launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $12 price target. The stock closed at $3.39 on Nov. 21. Hepion is developing CRV431, a novel pleiotropic...

November 22, 2019